Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that can persist into adulthood, with a course that impacts brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities. Subsequently, ADHD is associated with an increased risk of morbidity and mortality. It is imperative to acknowledge the whole-being impact of ADHD as well as the variable consequences of this disorder as the individual transitions from childhood to adulthood. This increased awareness should not only facilitate a better understanding of the seriousness of the condition but also provide an impetus to seek and implement treatment.
The first installment of this 4-part CME Outfitters series on ADHD will feature a discussion by Drs. Ann Childress and Thomas E. Brown on the extensive burden and impact of ADHD in children and adults. Additionally, the activity will include the use of a 3-D model highlighting the various systems and domains impacted.
At the end of this CME/CE activity, participants should be able to identify the extensive burden imposed by ADHD, including brain morphology, cognitive and psychosocial functioning, and psychiatric and medical comorbidities.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry, primary care, and/or pediatrics.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports the following financial relationships: Consultant: : Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals. Research Support: : Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. Speakers Bureau: Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc. Other Financial or Material Support: Writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Brown reports the following Financial or Material Support: Royalties for publications from American Psychiatric Publishing; Jossey-Bass/John Wiley; Routledge; and Yale University Press
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.